Incretins and preservation of endothelial function

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 10, Issue 4, 2012, Pages 295-308

  Koska, Juraj ^a  

^a Research Service   (United States)

Author keywords

Cardiovascular risk; DPP 4 inhibitors; Endothelium; eNOS; GLP 1; GLP 1 analogs; Incretins; Insulin resistance; Nitric oxide; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCHOLINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIACYLGLYCEROL; DIPEPTIDYL PEPTIDASE IV; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GUANYLATE CYCLASE; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INCRETIN; INSULIN RECEPTOR SUBSTRATE; LINAGLIPTIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SAXAGLIPTIN; SITAGLIPTIN; UNINDEXED DRUG; VILDAGLIPTIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOTHELIUM, VASCULAR; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN RESISTANCE; NITRIC OXIDE SYNTHASE TYPE III;

EID: 84870262663     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/187152512803530289     Document Type: Article

References (199)

1. Feskens, E.J.; Kromhout, D. Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. J. Clin. Epidemiol., 1992, 45(11), 1327-1334.
2. Newman, J.M.; DeStefano, F.; Valway, S.E.; German, R.R.; Muneta, B. Diabetes-associated mortality in Native Americans. Diabetes Care, 1993, 16(1), 297-299.
3. You, R.X.; McNeil, J.J.; O'Malley, H.M.; Davis, S.M.; Thrift, A.G.; Donnan, G.A. Risk factors for stroke due to cerebral infarction in young adults. Stroke, 1997, 28(10), 1913-1918.
4. Kannel, W.B.; McGee, D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA, 1979, 241(19), 2035-2038.
5. Pan, W.H.; Cedres, L.B.; Liu, K.; Dyer, A.; Schoenberger, J.A.; Shekelle, R.B.; Stamler, R.; Smith, D.; Collette, P.; Stamler, J. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am. J. Epidemiol., 1986, 123(3), 504-516.
6. Gerstein, H.C.; Miller, M.E.; Byington, R.P.; Goff, D.C., Jr.; Bigger, J.T.; Buse, J.B.; Cushman, W.C.; Genuth, S.; Ismail-Beigi, F.; Grimm, R.H., Jr.; Probstfield, J.L.; Simons-Morton, D.G.; Friedewald, W.T. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med., 2008, 358(24), 2545-2559.
7. Duckworth, W.; Abraira, C.; Moritz, T.; Reda, D.; Emanuele, N.; Reaven, P.D.; Zieve, F.J.; Marks, J.; Davis, S.N.; Hayward, R.; Warren, S.R.; Goldman, S.; McCarren, M.; Vitek, M.E.; Henderson, W.G.; Huang, G.D. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med., 2009, 360(2), 129-139.
8. Patel, A.; MacMahon, S.; Chalmers, J.; Neal, B.; Billot, L.; Woodward, M.; Marre, M.; Cooper, M.; Glasziou, P.; Grobbee, D.; Hamet, P.; Harrap, S.; Heller, S.; Liu, L.; Mancia, G.; Mogensen, C.E.; Pan, C.; Poulter, N.; Rodgers, A.; Williams, B.; Bompoint, S.; de Galan, B.E.; Joshi, R.; Travert, F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2008, 358(24), 2560-2572.
9. Halcox, J.P.; Schenke, W.H.; Zalos, G.; Mincemoyer, R.; Prasad, A.; Waclawiw, M.A.; Nour, K.R.; Quyyumi, A.A. Prognostic value of coronary vascular endothelial dysfunction. Circulation, 2002, 106(6), 653-658.
10. Basu, A.; Charkoudian, N.; Schrage, W.; Rizza, R.A.; Basu, R.; Joyner, M.J. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am. J. Physiol. Endocrinol. Metab., 2007, 293(5), E1289-1295.
11. Ceriello, A.; Esposito, K.; Testa, R.; Bonfigli, A.R.; Marra, M.; Giugliano, D. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an endothelial resistance to glucagon-like peptide 1 in diabetes. Diabetes Care, 2011, 34(3), 697-702.
12. Nystrom, T.; Gutniak, M. K.; Zhang, Q.; Zhang, F.; Holst, J.J.; Ahren, B.; Sjoholm, A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab., 2004, 287(6), E1209-15.
13. Koska, J.; Schwartz, E.A.; Mullin, M.P.; Schwenke, D.C.; Reaven, P.D. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care, 2010, 33(5), 1028-1030.
14. van Poppel, P.C. M.; Netea, M.G.; Smits, P.; Tack, C.J. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care, 2011, 34(9), 2072-2077.
15. Tabit, C.E.; Chung, W.B.; Hamburg, N.M.; Vita, J.A. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev. Endocr. Metab. Disord., 2010, 11(1), 61-74.
16. Widlansky, M.E.; Gokce, N.; Keaney, J.F., Jr.; Vita, J.A. The clinical implications of endothelial dysfunction. J. Am. Coll. Cardiol., 2003, 42(7), 1149-1160.
17. Palmer, R.M.J.; Ferrige, A.G.; Moncada, S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature, 1987, 327(6122), 524-526.
18. Griffith, T.M.; Edwards, D.H.; Lewis, M.J.; Newby, A.C.; Henderson, A.H. The nature of endothelium-derived vascular relaxant factor. Nature, 1984, 308(5960), 645-647.
19. Furchgott, R.F.; Martin, W. Interactions of endothelial cells and smooth muscle cells of arteries. Chest, 1985, 88(4 Suppl.), 210S-213S.
20. Shaul, P.W.; Smart, E.J.; Robinson, L.J.; German, Z.; Yuhanna, I.S.; Ying, Y.; Anderson, R.G.; Michel, T. Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae. J. Biol. Chem., 1996, 271(11), 6518-6522.
21. Feron, O.; Belhassen, L.; Kobzik, L.; Smith, T.W.; Kelly, R.A.; Michel, T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J. Biol. Chem., 1996, 271(37), 22810-22814.
22. Garcia-Cardena, G.; Fan, R.; Shah, V.; Sorrentino, R.; Cirino, G.; Papapetropoulos, A.; Sessa, W.C. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature, 1998, 392(6678), 821-824.
23. Haynes, M.P.; Sinha, D.; Russell, K.S.; Collinge, M.; Fulton, D.; Morales-Ruiz, M.; Sessa, W.C.; Bender, J.R. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ. Res., 2000, 87(8), 677-682.
24. Russell, K.S.; Haynes, M.P.; Caulin-Glaser, T.; Rosneck, J.; Sessa, W.C.; Bender, J.R. Estrogen stimulates heat shock protein 90 binding to endothelial nitric oxide synthase in human vascular endothelial cells. Effects on calcium sensitivity and NO release. J. Biol. Chem., 2000, 275(7), 5026-5030.
25. Michel, J.B.; Feron, O.; Sacks, D.; Michel, T. Reciprocal regulation of endothelial nitric-oxide synthase by Ca2+-calmodulin and caveolin. J. Biol. Chem., 1997, 272(25), 15583-15586.
26. Huang, P.L.; Huang, Z.; Mashimo, H.; Bloch, K.D.; Moskowitz, M.A.; Bevan, J.A.; Fishman, M.C. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature, 1995, 377(6546), 239-242.
27. Zhang, X.P.; Hintze, T.H. cAMP signal transduction induces eNOS activation by promoting PKB phosphorylation. Am. J. Physiol. Heart Circ. Physiol., 2006, 290(6), H2376-2384.
28. Chen, Z.P.; Mitchelhill, K.I.; Michell, B.J.; Stapleton, D.; Rodriguez-Crespo, I.; Witters, L.A.; Power, D.A.; Ortiz de Montellano, P.R.; Kemp, B.E. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett., 1999, 443(3), 285-289.
29. Michell, B.J.; Chen, Z.; Tiganis, T.; Stapleton, D.; Katsis, F.; Power, D.A.; Sim, A.T.; Kemp, B.E. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J. Biol. Chem., 2001, 276(21), 17625-17628.
30. Malek, A.M.; Alper, S.L.; Izumo, S. Hemodynamic shear stress and its role in atherosclerosis. JAMA, 1999, 282(21), 2035-2042.
31. Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 1999, 399(6736), 601-605.
32. Michell, B.J.; Griffiths, J.E.; Mitchelhill, K.I.; Rodriguez-Crespo, I.; Tiganis, T.; Bozinovski, S.; de Montellano, P.R.; Kemp, B.E.; Pearson, R.B. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr. Biol., 1999, 9(15), 845-848.
33. Zeng, G.; Nystrom, F.H.; Ravichandran, L.V.; Cong, L.N.; Kirby, M.; Mostowski, H.; Quon, M.J. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation, 2000, 101(13), 1539-1545.
34. Bellis, A.; Castaldo, D.; Trimarco, V.; Monti, M.G.; Chivasso, P.; Sadoshima, J.; Trimarco, B.; Morisco, C. Cross-talk between PKA and Akt protects endothelial cells from apoptosis in the late ischemic preconditioning. Arterioscler. Thromb. Vasc. Biol., 2009, 29(8), 1207-1212.
35. Fisslthaler, B.; Fleming, I. Activation and Signaling by the AMPActivated Protein Kinase in Endothelial Cells. Circ. Res., 2009, 105(2), 114-127.
36. Eringa, E.C.; Stehouwer, C.D.; van Nieuw Amerongen, G.P.; Ouwehand, L.; Westerhof, N.; Sipkema, P. Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium. Am. J. Physiol. Heart Circ. Physiol., 2004, 287(5), H2043-2048.
37. Wang, Y.; Cheng, K.K.; Lam, K.S.; Wu, D.; Huang, Y.; Vanhoutte, P.M.; Sweeney, G.; Li, Y.; Xu, A. APPL1 counteracts obesityinduced vascular insulin resistance and endothelial dysfunction by modulating the endothelial production of nitric oxide and endothelin-1 in mice. Diabetes, 2011, 60(11), 3044-3054.
38. Silver, A.E.; Vita, J.A. Shear-stress-mediated arterial remodeling in atherosclerosis: too much of a good thing? Circulation, 2006, 113(24), 2787-2789.
39. Sprague, A.H.; Khalil, R.A. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem. Pharmacol., 2009, 78(6), 539-552.
40. Deanfield, J.; Donald, A.; Ferri, C.; Giannattasio, C.; Halcox, J.; Halligan, S.; Lerman, A.; Mancia, G.; Oliver, J.J.; Pessina, A.C.; Rizzoni, D.; Rossi, G.P.; Salvetti, A.; Schiffrin, E.L.; Taddei, S.; Webb, D.J. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J. Hypertens., 2005, 23(1), 7-17.
41. Hamilton, S.J.; Chew, G.T.; Watts, G.F. Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diab. Vasc. Dis. Res., 2007, 4(2), 89-102.
42. Stehouwer, C.D.; Stroes, E.S.; Hackeng, W.H.; Mulder, P.G.; Den Ottolander, G.J. von Willebrand factor and development of diabetic nephropathy in IDDM. Diabetes, 1991, 40(8), 971-976.
43. Jensen, T.; Bjerre-Knudsen, J.; Feldt-Rasmussen, B.; Deckert, T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet, 1989, 1(8636), 461-463.
44. Hwang, S.J.; Ballantyne, C.M.; Sharrett, A.R.; Smith, L.C.; Davis, C.E.; Gotto, A.M., Jr.; Boerwinkle, E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation, 1997, 96(12), 4219-4225.
45. Ridker, P.M.; Hennekens, C.H.; Roitman-Johnson, B.; Stampfer, M.J.; Allen, J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet, 1998, 351(9096), 88-92.
46. Hill, J.M.; Zalos, G.; Halcox, J.P.; Schenke, W.H.; Waclawiw, M.A.; Quyyumi, A.A.; Finkel, T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med., 2003, 348(7), 593-600.
47. Bonetti, P.O.; Lerman, L.O.; Lerman, A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol., 2003, 23(2), 168-175.
48. Ludmer, P.L.; Selwyn, A.P.; Shook, T.L.; Wayne, R.R.; Mudge, G.H.; Alexander, R.W.; Ganz, P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med., 1986, 315(17), 1046-1051.
49. Cox, D.A.; Vita, J.A.; Treasure, C.B.; Fish, R.D.; Alexander, R.W.; Ganz, P.; Selwyn, A.P. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation, 1989, 80(3), 458-465.
50. Nishimura, Y.; Usui, H.; Kurahashi, K.; Suzuki, A. Endotheliumdependent contraction induced by acetylcholine in isolated rat renal arteries. Eur. J. Pharmacol., 1995, 275(2), 217-221.
51. Suwaidi, J.A.; Hamasaki, S.; Higano, S.T.; Nishimura, R.A.; Holmes, D.R., Jr.; Lerman, A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation, 2000, 101(9), 948-954.
52. Schachinger, V.; Britten, M.B.; Zeiher, A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation, 2000, 101(16), 1899-1906.
53. Nitenberg, A.; Chemla, D.; Antony, I. Epicardial coronary artery constriction to cold pressor test is predictive of cardiovascular events in hypertensive patients with angiographically normal coronary arteries and without other major coronary risk factor. Atherosclerosis, 2004, 173(1), 115-123.
54. Nitenberg, A.; Valensi, P.; Sachs, R.; Cosson, E.; Attali, J.R.; Antony, I. Prognostic value of epicardial coronary artery constriction to the cold pressor test in type 2 diabetic patients with angiographically normal coronary arteries and no other major coronary risk factors. Diabetes Care, 2004, 27(1), 208-215.
55. Celermajer, D.S.; Sorensen, K.E.; Gooch, V.M.; Spiegelhalter, D.J.; Miller, O.I.; Sullivan, I.D.; Lloyd, J.K.; Deanfield, J.E. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 1992, 340(8828), 1111-1115.
56. Anderson, T.J.; Uehata, A.; Gerhard, M.D.; Meredith, I.T.; Knab, S.; Delagrange, D.; Lieberman, E.H.; Ganz, P.; Creager, M.A.; Yeung, A.C. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol., 1995, 26(5), 1235-1241.
57. Steinberg, H.O.; Chaker, H.; Leaming, R.; Johnson, A.; Brechtel, G.; Baron, A.D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest., 1996, 97(11), 2601-2610.
58. Steinberg, H.O.; Bayazeed, B.; Hook, G.; Johnson, A.; Cronin, J.; Baron, A.D. Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. Circulation, 1997, 96(10), 3287-3293.
59. Cosentino, F.; Luscher, T.F. Endothelial dysfunction in diabetes mellitus. J. Cardiovasc. Pharmacol., 1998, 32(Suppl. 3), S54-61.
60. Halcox, J.P.; Donald, A.E.; Ellins, E.; Witte, D.R.; Shipley, M.J.; Brunner, E.J.; Marmot, M.G.; Deanfield, J.E. Endothelial function predicts progression of carotid intima-media thickness. Circulation, 2009, 119(7), 1005-1012.
61. Gokce, N.; Keaney, J.F., Jr.; Hunter, L.M.; Watkins, M.T.; Menzoian, J.O.; Vita, J.A. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation, 2002, 105(13), 1567-1572.
62. Heitzer, T.; Schlinzig, T.; Krohn, K.; Meinertz, T.; Munzel, T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation, 2001, 104(22), 2673-2678.
63. Yeboah, J.; Crouse, J.R.; Hsu, F.C.; Burke, G.L.; Herrington, D.M. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation, 2007, 115(18), 2390-2397.
64. Huang, P.H.; Chen, J.W.; Lu, T.M.; Yu-An Ding, P.; Lin, S.J. Combined use of endothelial function assessed by brachial ultrasound and high-sensitive C-reactive protein in predicting cardiovascular events. Clin. Cardiol., 2007, 30(3), 135-140.
65. Panza, J.A.; Quyyumi, A.A.; Brush, J.E., Jr.; Epstein, S.E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med., 1990, 323(1), 22-27.
66. Frick, M.; Weidinger, F. Endothelial function: a surrogate endpoint in cardiovascular studies? Curr. Pharm. Des., 2007, 13(17), 1741-1750.
67. Higashi, Y.; Yoshizumi, M. New methods to evaluate endothelial function: method for assessing endothelial function in humans using a strain-gauge plethysmography: nitric oxide-dependent and -independent vasodilation. J. Pharmacol. Sci., 2003, 93(4), 399-404.
68. Celermajer, D.S. Reliable endothelial function testing: at our fingertips? Circulation, 2008, 117(19), 2428-2430.
69. Bonetti, P.O.; Pumper, G.M.; Higano, S.T.; Holmes, D.R., Jr.; Kuvin, J.T.; Lerman, A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J. Am. Coll. Cardiol., 2004, 44(11), 2137-2141.
70. Kuvin, J.T.; Patel, A.R.; Sliney, K.A.; Pandian, N.G.; Sheffy, J.; Schnall, R.P.; Karas, R.H.; Udelson, J.E. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am. Heart J., 2003, 146(1), 168-174.
71. Hamburg, N.M.; Keyes, M.J.; Larson, M.G.; Vasan, R.S.; Schnabel, R.; Pryde, M.M.; Mitchell, G.F.; Sheffy, J.; Vita, J.A.; Benjamin, E.J. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation, 2008, 117(19), 2467-2474.
72. Atochin, D.; Huang, P. Endothelial nitric oxide synthase transgenic models of endothelial dysfunction. Pflügers Arch., 2010, 460(6), 965-974.
73. Sorensen, K.E.; Celermajer, D.S.; Georgakopoulos, D.; Hatcher, G.; Betteridge, D.J.; Deanfield, J.E. Impairment of endotheliumdependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J. Clin. Invest., 1994, 93(1), 50-55.
74. Fichtlscherer, S.; Rosenberger, G.; Walter, D.H.; Breuer, S.; Dimmeler, S.; Zeiher, A.M. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation, 2000, 102(9), 1000-1006.
75. Prasad, A.; Zhu, J.; Halcox, J.P.; Waclawiw, M.A.; Epstein, S.E.; Quyyumi, A.A. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation, 2002, 106(2), 184-1890.
76. Guzik, T.J.; Mussa, S.; Gastaldi, D.; Sadowski, J.; Ratnatunga, C.; Pillai, R.; Channon, K.M. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation, 2002, 105(14), 1656-1662.
77. Beckman, J.S.; Koppenol, W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol., 1996, 271(5 Pt. 1), C1424-1437.
78. Zou, M.H.; Shi, C.; Cohen, R.A. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J. Clin. Invest., 2002, 109(6), 817-826.
79. Munzel, T.; Daiber, A.; Ullrich, V.; Mulsch, A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler. Thromb. Vasc. Biol., 2005, 25(8), 1551-1557.
80. Oeseburg, H.; Iusuf, D.; van der Harst, P.; van Gilst, W.H.; Henning, R.H.; Roks, A.J. Bradykinin protects against oxidative stress-induced endothelial cell senescence. Hypertension, 2009, 53(2), 417-422.
81. Sydow, K.; Munzel, T. ADMA and oxidative stress. Atheroscler. Suppl., 2003, 4(4), 41-51.
82. Anderson, R.A.; Evans, M.L.; Ellis, G.R.; Graham, J.; Morris, K.; Jackson, S.K.; Lewis, M.J.; Rees, A.; Frenneaux, M.P. The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis, 2001, 154(2), 475-483.
83. Bae, J.H.; Bassenge, E.; Lee, H.J.; Park, K.R.; Park, C.G.; Park, K.Y.; Lee, M.S.; Schwemmer, M. Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates. Atherosclerosis, 2001, 158(1), 165-171.
84. Ceriello, A.; Taboga, C.; Tonutti, L.; Quagliaro, L.; Piconi, L.; Bais, B.; Da Ros, R.; Motz, E. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short-and long-term simvastatin treatment. Circulation, 2002, 106(10), 1211-1218.
85. Kawano, H.; Motoyama, T.; Hirashima, O.; Hirai, N.; Miyao, Y.; Sakamoto, T.; Kugiyama, K.; Ogawa, H.; Yasue, H. Hyperglycemia rapidly suppresses flow-mediated endotheliumdependent vasodilation of brachial artery. J. Am. Coll. Cardiol., 1999, 34(1), 146-154.
86. Title, L.M.; Cummings, P.M.; Giddens, K.; Nassar, B.A. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. J. Am. Coll. Cardiol., 2000, 36(7), 2185-2191.
87. Plotnick, G.D.; Corretti, M.C.; Vogel, R.A. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA, 1997, 278(20), 1682-1686.
88. Mah, E.; Noh, S.K.; Ballard, K.D.; Matos, M.E.; Volek, J.S.; Bruno, R.S. Postprandial hyperglycemia impairs vascular endothelial function in healthy men by inducing lipid peroxidation and increasing asymmetric dimethylarginine: arginine. J. Nutr., 2011, 141(11), 1961-1968.
89. Marfella, R.; Verrazzo, G.; Acampora, R.; La Marca, C.; Giunta, R.; Lucarelli, C.; Paolisso, G.; Ceriello, A.; Giugliano, D. Glutathione reverses systemic hemodynamic changes induced by acute hyperglycemia in healthy subjects. Am. J. Physiol., 1995, 268(6 Pt. 1), E1167-1173.
90. Ceriello, A.; Esposito, K.; Piconi, L.; Ihnat, M.A.; Thorpe, J.E.; Testa, R.; Boemi, M.; Giugliano, D. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes, 2008, 57(5), 1349-1354.
91. McVeigh, G.E.; Brennan, G.M.; Johnston, G.D.; McDermott, B.J.; McGrath, L.T.; Henry, W.R.; Andrews, J.W.; Hayes, J.R. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 1992, 35(8), 771-776.
92. Williams, S.B.; Cusco, J.A.; Roddy, M.A.; Johnstone, M.T.; Creager, M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol., 1996, 27(3), 567-574.
93. Meigs, J.B.; Mittleman, M.A.; Nathan, D.M.; Tofler, G.H.; Singer, D.E.; Murphy-Sheehy, P.M.; Lipinska, I.; D'Agostino, R.B.; Wilson, P.W. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA, 2000, 283(2), 221-228.
94. Keaney, J.F., Jr.; Massaro, J.M.; Larson, M.G.; Vasan, R.S.; Wilson, P.W.; Lipinska, I.; Corey, D.; Sutherland, P.; Vita, J.A.; Benjamin, E.J. Heritability and correlates of intercellular adhesion molecule-1 in the Framingham Offspring Study. J. Am. Coll. Cardiol., 2004, 44(1), 168-173.
95. Steinberg, H.O.; Tarshoby, M.; Monestel, R.; Hook, G.; Cronin, J.; Johnson, A.; Bayazeed, B.; Baron, A.D. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J. Clin. Invest., 1997, 100(5), 1230-1239.
96. Goodfellow, J.; Ramsey, M.W.; Luddington, L.A.; Jones, C.J.; Coates, P.A.; Dunstan, F.; Lewis, M.J.; Owens, D.R.; Henderson, A.H. Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin dependent diabetes. BMJ, 1996, 312(7033), 744-745.
97. Caballero, A.E.; Saouaf, R.; Lim, S.C.; Hamdy, O.; Abou-Elenin, K.; O'Connor, C.; Logerfo, F.W.; Horton, E.S.; Veves, A. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebocontrolled randomized clinical trial. Metabolism, 2003, 52(2), 173-180.
98. Suzuki, M.; Takamisawa, I.; Yoshimasa, Y.; Harano, Y. Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. Diabetes Res. Clin. Pract., 2007, 76(1), 12-17.
99. Pistrosch, F.; Passauer, J.; Fischer, S.; Fuecker, K.; Hanefeld, M.; Gross, P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care, 2004, 27(2), 484-490.
100. Mather, K.J.; Verma, S.; Anderson, T.J. Improved endothelial function with metformin in type 2 diabetes mellitus. J. Am. Coll. Cardiol., 2001, 37(5), 1344-1350.
101. Natali, A.; Baldeweg, S.; Toschi, E.; Capaldo, B.; Barbaro, D.; Gastaldelli, A.; Yudkin, J.S.; Ferrannini, E. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care, 2004, 27(6), 1349-1357.
102. Hamdy, O.; Ledbury, S.; Mullooly, C.; Jarema, C.; Porter, S.; Ovalle, K.; Moussa, A.; Caselli, A.; Caballero, A.E.; Economides, P.A.; Veves, A.; Horton, E.S. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care, 2003, 26(7), 2119-2125.
103. Maiorana, A.; O'Driscoll, G.; Cheetham, C.; Dembo, L.; Stanton, K.; Goodman, C.; Taylor, R.; Green, D. The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. J. Am. Coll. Cardiol., 2001, 38(3), 860-866.
104. Takenouchi, Y.; Kobayashi, T.; Matsumoto, T.; Kamata, K. Possible involvement of Akt activity in endothelial dysfunction in type 2 diabetic mice. J. Pharmacol. Sci., 2008, 106(4), 600-608.
105. Montagnani, M.; Golovchenko, I.; Kim, I.; Koh, G.Y.; Goalstone, M.L.; Mundhekar, A.N.; Johansen, M.; Kucik, D.F.; Quon, M.J.; Draznin, B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J. Biol. Chem., 2002, 277(3), 1794-1799.
106. Bourgoin, F.; Bachelard, H.; Badeau, M.; Melancon, S.; Pitre, M.; Lariviere, R.; Nadeau, A. Endothelial and vascular dysfunctions and insulin resistance in rats fed a high-fat, high-sucrose diet. Am. J. Physiol. Heart Circ. Physiol., 2008, 295(3), H1044-H1055.
107. Meigs, J.B.; Hu, F.B.; Rifai, N.; Manson, J.E. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA, 2004, 291(16), 1978-1986.
108. Meigs, J.B.; Larson, M.G.; Fox, C.S.; Keaney, J.F., Jr.; Vasan, R.S.; Benjamin, E.J. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care, 2007, 30(10), 2529-2535.
109. Keaney, J.F., Jr.; Larson, M.G.; Vasan, R.S.; Wilson, P.W.; Lipinska, I.; Corey, D.; Massaro, J.M.; Sutherland, P.; Vita, J.A.; Benjamin, E.J. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler. Thromb. Vasc. Biol., 2003, 23(3), 434-439.
110. Gupte, S.; Labinskyy, N.; Gupte, R.; Csiszar, A.; Ungvari, Z.; Edwards, J.G. Role of NAD(P)H oxidase in superoxide generation and endothelial dysfunction in Goto-Kakizaki (GK) rats as a model of nonobese NIDDM. PLoS ONE, 2010, 5(7), e11800.
111. Wautier, M.-P.; Chappey, O.; Corda, S.; Stern, D.M.; Schmidt, A. M.; Wautier, J.-L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab., 2001, 280(5), E685-E694.
112. Shin, H.K.; Kim, Y.K.; Kim, K.Y.; Lee, J.H.; Hong, K.W. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-"mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation. Circulation, 2004, 109(8), 1022-1028.
113. Chinen, I.; Shimabukuro, M.; Yamakawa, K.; Higa, N.; Matsuzaki, T.; Noguchi, K.; Ueda, S.; Sakanashi, M.; Takasu, N. Vascular Lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology, 2007, 148(1), 160-165.
114. Li, J.-M.; Shah, A.M. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. J. Biol. Chem., 2003, 278(14), 12094-12100.
115. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature, 2001, 414(6865), 813-820.
116. Shenouda, S.M.; Widlansky, M.E.; Chen, K.; Xu, G.; Holbrook, M.; Tabit, C.E.; Hamburg, N.M.; Frame, A.A.; Caiano, T.L.; Kluge, M.A.; Duess, M.A.; Levit, A.; Kim, B.; Hartman, M.L.; Joseph, L.; Shirihai, O.S.; Vita, J.A. Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation, 2011, 124(4), 444-453.
117. Shmueli, E.; Alberti, K.G.; Record, C.O. Diacylglycerol/protein kinase C signalling: a mechanism for insulin resistance? J. Intern. Med., 1993, 234(4), 397-400.
118. Kuboki, K.; Jiang, Z.Y.; Takahara, N.; Ha, S.W.; Igarashi, M.; Yamauchi, T.; Feener, E.P.; Herbert, T.P.; Rhodes, C.J.; King, G.L. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: A specific vascular action of insulin. Circulation, 2000, 101(6), 676-681.
119. Tesfamariam, B.; Brown, M.L.; Cohen, R.A. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J. Clin. Invest., 1991, 87(5), 1643-1648.
120. Naruse, K.; Rask-Madsen, C.; Takahara, N.; Ha, S.W.; Suzuma, K.; Way, K.J.; Jacobs, J. R.; Clermont, A.C.; Ueki, K.; Ohshiro, Y.; Zhang, J.; Goldfine, A.B.; King, G.L. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes, 2006, 55(3), 691-698.
121. Nisoli, E.; Clementi, E.; Paolucci, C.; Cozzi, V.; Tonello, C.; Sciorati, C.; Bracale, R.; Valerio, A.; Francolini, M.; Moncada, S.; Carruba, M.O. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science, 2003, 299(5608), 896-899.
122. Park, J.Y.; Takahara, N.; Gabriele, A.; Chou, E.; Naruse, K.; Suzuma, K.; Yamauchi, T.; Ha, S.W.; Meier, M.; Rhodes, C.J.; King, G.L. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes, 2000, 49(7), 1239-1248.
123. Huang, A.L.; Vita, J.A. Effects of systemic inflammation on endothelium-dependent vasodilation. Trends Cardiovasc. Med., 2006, 16(1), 15-20.
124. Kim, F.; Tysseling, K.A.; Rice, J.; Pham, M.; Haji, L.; Gallis, B.M.; Baas, A.S.; Paramsothy, P.; Giachelli, C.M.; Corson, M.A.; Raines, E.W. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler. Thromb. Vasc. Biol., 2005, 25(5), 989-994.
125. Donato, A.J.; Black, A.D.; Jablonski, K.L.; Gano, L.B.; Seals, D.R. Aging is associated with greater nuclear NF kappa B, reduced I kappa B alpha, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell, 2008, 7(6), 805-812.
126. Maloney, E.; Sweet, I.R.; Hockenbery, D.M.; Pham, M.; Rizzo, N.O.; Tateya, S.; Handa, P.; Schwartz, M.W.; Kim, F. Activation of NF-kappaB by palmitate in endothelial cells: a key role for NADPH oxidase-derived superoxide in response to TLR4 activation. Arterioscler. Thromb. Vasc. Biol., 2009, 29(9), 1370-1375.
127. Itani, S.I.; Ruderman, N.B.; Schmieder, F.; Boden, G. Lipidinduced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes, 2002, 51(7), 2005-2011.
128. De Martin, R.; Hoeth, M.; Hofer-Warbinek, R.; Schmid, J.A. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler. Thromb. Vasc. Biol., 2000, 20(11), E83-88.
129. Pierce, G.L.; Lesniewski, L.A.; Lawson, B.R.; Beske, S.D.; Seals, D.R. Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation, 2009, 119(9), 1284-1292.
130. Peng, H.B.; Libby, P.; Liao, J.K. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J. Biol. Chem., 1995, 270(23), 14214-14219.
131. Pradhan, A.D.; Manson, J.E.; Rifai, N.; Buring, J.E.; Ridker, P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 2001, 286(3), 327-334.
132. Verma, S.; Wang, C.H.; Li, S.H.; Dumont, A.S.; Fedak, P.W.; Badiwala, M.V.; Dhillon, B.; Weisel, R.D.; Li, R.K.; Mickle, D.A.; Stewart, D.J. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation, 2002, 106(8), 913-919.
133. Chia, S.; Qadan, M.; Newton, R.; Ludlam, C.A.; Fox, K. A.A.; Newby, D.E. Intra-arterial tumor necrosis factor-impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler. Thromb. Vasc. Biol., 2003, 23(4), 695-701.
134. Zhang, J.; Patel, J.M.; Li, Y.D.; Block, E.R. Proinflammatory cytokines downregulate gene expression and activity of constitutive nitric oxide synthase in porcine pulmonary artery endothelial cells. Res. Commun. Mol. Pathol. Pharmacol., 1997, 96(1), 71-87.
135. Hingorani, A.D.; Cross, J.; Kharbanda, R.K.; Mullen, M.J.; Bhagat, K.; Taylor, M.; Donald, A.E.; Palacios, M.; Griffin, G.E.; Deanfield, J.E.; MacAllister, R.J.; Vallance, P. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation, 2000, 102(9), 994-999.
136. Bhagat, K.; Moss, R.; Collier, J.; Vallance, P. Endothelial stunning following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc. Res., 1996, 32(5), 822-829.
137. Bucci, M.; Roviezzo, F.; Brancaleone, V.; Lin, M.I.; Di Lorenzo, A.; Cicala, C.; Pinto, A.; Sessa, W.C.; Farneti, S.; Fiorucci, S.; Cirino, G. Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression. Arterioscler. Thromb. Vasc. Biol., 2004, 24(4), 721-726.
138. Catalan, V.; Gomez-Ambrosi, J.; Rodriguez, A.; Silva, C.; Rotellar, F.; Gil, M.J.; Cienfuegos, J.A.; Salvador, J.; Fruhbeck, G. Expression of caveolin-1 in human adipose tissue is upregulated in obesity and obesity-associated type 2 diabetes mellitus and related to inflammation. Clin. Endocrinol. (Oxf), 2008, 68(2), 213-219.
139. Lei, H.; Venkatakrishnan, A.; Yu, S.; Kazlauskas, A. Protein kinase A-dependent translocation of Hsp90 alpha impairs endothelial nitric-oxide synthase activity in high glucose and diabetes. J. Biol. Chem., 2007, 282(13), 9364-9371.
140. Lin, K.Y.; Ito, A.; Asagami, T.; Tsao, P.S.; Adimoolam, S.; Kimoto, M.; Tsuji, H.; Reaven, G.M.; Cooke, J.P. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation, 2002, 106(8), 987-992.
141. Pierce, G.L.; Beske, S.D.; Lawson, B.R.; Southall, K.L.; Benay, F.J.; Donato, A.J.; Seals, D.R. Weight Loss Alone Improves Conduit and Resistance Artery Endothelial Function in Young and Older Overweight/Obese Adults. Hypertension, 2008, 52(1), 72-79.
142. Mangoni, A.A.; Sherwood, R.A.; Asonganyi, B.; Swift, C.G.; Thomas, S.; Jackson, S.H. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am. J. Hypertens., 2005, 18(2 Pt. 1), 220-226.
143. Fernandez, M.; Triplitt, C.; Wajcberg, E.; Sriwijilkamol, A.A.; Musi, N.; Cusi, K.; DeFronzo, R.; Cersosimo, E. Addition of Pioglitazone and Ramipril to Intensive Insulin Therapy in Type 2 Diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care, 2008, 31(1), 121-127.
144. Okerson, T.; Chilton, R.J. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc. Ther., 2012, 30(3), e146-e155.
145. Inzucchi, S.E.; McGuire, D.K. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation, 2008, 117(4), 574-584.
146. Drucker, D.J. The biology of incretin hormones. Cell Metab., 2006, 3(3), 153-165.
147. Kreymann, B.; Williams, G.; Ghatei, M.A.; Bloom, S.R. Glucagonlike peptide-1 7-36: a physiological incretin in man. Lancet, 1987, 2(8571), 1300-1304.
148. Usdin, T.B.; Mezey, E.; Button, D.C.; Brownstein, M.J.; Bonner, T.I. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology, 1993, 133(6), 2861-2870.
149. Nauck, M.A.; Heimesaat, M.M.; Orskov, C.; Holst, J.J.; Ebert, R.; Creutzfeldt, W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest., 1993, 91(1), 301-307.
150. Willms, B.; Werner, J.; Holst, J.J.; Orskov, C.; Creutzfeldt, W.; Nauck, M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagonlike peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulindependent) diabetic patients. J. Clin. Endocrinol. Metab., 1996, 81(1), 327-332.
151. Naslund, E.; Barkeling, B.; King, N.; Gutniak, M.; Blundell, J.E.; Holst, J.J.; Rossner, S.; Hellstrom, P.M. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int. J. Obes. Relat. Metab. Disord., 1999, 23(3), 304-311.
152. Flint, A.; Raben, A.; Astrup, A.; Holst, J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest., 1998, 101(3), 515-520.
153. Nauck, M.; Stockmann, F.; Ebert, R.; Creutzfeldt, W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia, 1986, 29(1), 46-52.
154. Toft-Nielsen, M.B.; Damholt, M.B.; Madsbad, S.; Hilsted, L.M.; Hughes, T.E.; Michelsen, B.K.; Holst, J.J. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J. Clin. Endocrinol. Metab., 2001, 86(8), 3717-3723.
155. Kieffer, T.J.; McIntosh, C.H.; Pederson, R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology, 1995, 136(8), 3585-3596.
156. Fineman, M.S.; Bicsak, T.A.; Shen, L.Z.; Taylor, K.; Gaines, E.; Varns, A.; Kim, D.; Baron, A.D. Effect on glycemic control of exenatide (Synthetic Exendin-4) additive to existing Metformin and/or Sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care, 2003, 26(8), 2370-2377.
157. Klonoff, D.C.; Buse, J.B.; Nielsen, L.L.; Guan, X.; Bowlus, C.L.; Holcombe, J.H.; Wintle, M.E.; Maggs, D.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin., 2008, 24(1), 275-286.
158. Diamant, M.; Van Gaal, L.; Stranks, S.; Northrup, J.; Cao, D.; Taylor, K.; Trautmann, M. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet, 2010, 375(9733), 2234-2243.
159. Bergenstal, R.M.; Wysham, C.; MacConell, L.; Malloy, J.; Walsh, B.; Yan, P.; Wilhelm, K.; Malone, J.; Porter, L.E. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet, 2010, 376(9739), 431-439.
160. Vilsbøll, T.; Zdravkovic, M.; Le-Thi, T.; Krarup, T.; Schmitz, O.; Courreges, J.P.; Verhoeven, R.; Buganova, I.; Madsbad, S. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care, 2007, 30(6), 1608-1610.
161. Ryan, G.J.; Foster, K.T.; Jobe, L.J. Review of the therapeutic uses of liraglutide. Clin. Ther., 2011, 33(7), 793-811.
162. Buse, J.B.; Rosenstock, J.; Sesti, G.; Schmidt, W.E.; Montanya, E.; Brett, J.H.; Zychma, M.; Blonde, L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, 2009, 374(9683), 39-47.
163. Vilsbøll, T.; Christensen, M.; Junker, A.E.; Knop, F.K.; Gluud, L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ, 2012, 344, d7771.
164. Monami, M.; Iacomelli, I.; Marchionni, N.; Mannucci, E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a metaanalysis of randomized clinical trials. Nutr. Metab. Cardiovasc. Dis., 2009, 20(4), 224-235.
165. Best, J.H.; Hoogwerf, B.J.; Herman, W.H.; Pelletier, E.M.; Smith, D.B.; Wenten, M.; Hussein, M.A. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the Glucagon-Like Peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies. Diabetes Care, 2011, 34(1), 90-95.
166. Williams-Herman, D.; Engel, S.S.; Round, E.; Johnson, J.; Golm, G.T.; Guo, H.; Musser, B.J.; Davies, M.J.; Kaufman, K.D.; Goldstein, B.J. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr. Disord., 2010, 10, 7.
167. Peskin, B.R.; Shcheprov, A.V.; Boye, K.S.; Bruce, S.; Maggs, D.G.; Gaebler, J.A. Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis. Diabetes. Obes. Metab., 2011, 13(10), 921-927.
168. Ban, K.; Noyan-Ashraf, M.H.; Hoefer, J.; Bolz, S.S.; Drucker, D.J.; Husain, M. Cardioprotective and vasodilatory actions of glucagonlike peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation, 2008, 117(18), 2340-2350.
169. Buteau, J.; Roduit, R.; Susini, S.; Prentki, M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia, 1999, 42(7), 856-864.
170. Wang, J.; Alexanian, A.; Ying, R.; Kizhakekuttu, T.J.; Dharmashankar, K.; Vasquez-Vivar, J.; Gutterman, D.D.; Widlansky, M.E. Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase. Arterioscler. Thromb. Vasc. Biol., 2012, 32(3), 712-720.
171. Erdogdu, A.; Nathanson, D.; Sjoholm, A.; Nystrom, T.; Zhang, Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA-and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol. Cell. Endocrinol., 2010, 325(1-2), 26-35.
172. Liu, H.; Hu, Y.; Simpson, R.W.; Dear, A.E. Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasmogen activator inhibitor-1 expression. J. Endocrinol., 2008, 196(1), 57-65.
173. Ishibashi, Y.; Matsui, T.; Takeuchi, M.; Yamagishi, S. Glucagonlike peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem. Biophys. Res. Commun., 2010, 391(3), 1405-1408.
174. Gaspari, T.; Hong Bin Liu; Welungoda, I.; Yunshan Hu; Widdop, R.E.; Knudsen, L.B.; Simpson, R.W.; Dear, A.E. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/-mouse model. Diab. Vasc. Dis. Res., 2011, 8(2), 117-124.
175. Oeseburg, H.; de Boer, R.A.; Buikema, H.; van der Harst, P.; van Gilst, W.H.; Sillje, H.H. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler. Thromb. Vasc. Biol., 2010, 30(7), 1407-1414.
176. Richter, G.; Feddersen, O.; Wagner, U.; Barth, P.; Goke, R.; Goke, B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am. J. Physiol., 1993, 265(4 Pt. 1), L374-381.
177. Yu, M.; Moreno, C.; Hoagland, K.M.; Dahly, A.; Ditter, K.; Mistry, M.; Roman, R.J. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J. Hypertens., 2003, 21(6), 1125-1135.
178. Ray, C.J.; Marshall, J.M. The cellular mechanisms by which adenosine evokes release of nitric oxide from rat aortic endothelium. J. Physiol., 2006, 570(1), 85-96.
179. Lim, A.; Park, S.H.; Sohn, J.W.; Jeon, J.H.; Park, J.H.; Song, D.K.; Lee, S.H.; Ho, W.K. Glucose deprivation regulates KATP channel trafficking via AMP-activated protein kinase in pancreatic betacells. Diabetes, 2009, 58(12), 2813-2819.
180. Ha, S.J.; Kim, W.; Woo, J.S.; Kim, J.B.; Kim, S.J.; Kim, W.-S.; Kim, M.K.; Cheng, X.W.; Kim, K.S. Preventive effects of exenatide on endothelial dysfunction induced by Ischemia-Reperfusion injury via KATP channels. Arterioscler. Thromb. Vasc. Biol., 2012, 32(2), 474-480.
181. Fadini, G.P.; Boscaro, E.; Albiero, M.; Menegazzo, L.; Frison, V.; de Kreutzenberg, S.; Agostini, C.; Tiengo, A.; Avogaro, A. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes. Diabetes Care, 2010, 33(7), 1607-1609.
182. Shah, Z.; Kampfrath, T.; Deiuliis, J.A.; Zhong, J.; Pineda, C.; Ying, Z.; Xu, X.; Lu, B.; Moffatt-Bruce, S.; Durairaj, R.; Sun, Q.; Mihai, G.; Maiseyeu, A.; Rajagopalan, S. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis / clinical perspective. Circulation, 2011, 124(21), 2338-2349.
183. Ban, K.; Kim, K.-H.; Cho, C.-K.; Sauve, M.; Diamandis, E.P.; Backx, P.H.; Drucker, D.J.; Husain, M. Glucagon-Like Peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology, 2010, 151(4), 1520-1531.
184. Nathanson, D.; Erdogdu, O.; Pernow, J.; Zhang, Q.; Nystrom, T. Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul. Pept., 2009, 157(1-3), 8-13.
185. Zhong, Q.; Bollag, R.J.; Dransfield, D.T.; Gasalla-Herraiz, J.; Ding, K.H.; Min, L.; Isales, C.M. Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells. Peptides, 2000, 21(9), 1427-1432.
186. Ding, K.H.; Zhong, Q.; Isales, C.M. Glucose-dependent insulinotropic peptide stimulates thymidine incorporation in endothelial cells: role of endothelin-1. Am. J. Physiol. Endocrinol. Metab., 2003, 285(2), E390-396.
187. Kogire, M.; Inoue, K.; Sumi, S.; Doi, R.; Takaori, K.; Yun, M.; Fujii, N.; Yajima, H.; Tobe, T. Effects of synthetic human gastric inhibitory polypeptide on splanchnic circulation in dogs. Gastroenterology, 1988, 95(6), 1636-1640.
188. Cervera, A.; Wajcberg, E.; Sriwijitkamol, A.; Fernandez, M.; Zuo, P.; Triplitt, C.; Musi, N.; DeFronzo, R.A.; Cersosimo, E. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab., 2008, 294(5), E846-852.
189. Deane, A.M.; Nguyen, N.Q.; Stevens, J.E.; Fraser, R.J.L.; Holloway, R.H.; Besanko, L.K.; Burgstad, C.; Jones, K.L.; Chapman, M.J.; Rayner, C.K.; Horowitz, M. Endogenous glucagon-like Peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J. Clin. Endocrinol. Metab., 2010, 95(1), 215-221.
190. DeFronzo, R.A.; Okerson, T.; Viswanathan, P.; Guan, X.; Holcombe, J.H.; MacConell, L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr. Med. Res. Opin., 2008, 24(10), 2943-2952.
191. Edwards, C.M.; Stanley, S.A.; Davis, R.; Brynes, A.E.; Frost, G.S.; Seal, L.J.; Ghatei, M.A.; Bloom, S.R. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. Endocrinol. Metab., 2001, 281(1), E155-161.
192. Kolterman, O.G.; Buse, J.B.; Fineman, M.S.; Gaines, E.; Heintz, S.; Bicsak, T.A.; Taylor, K.; Kim, D.; Aisporna, M.; Wang, Y.; Baron, A.D. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab., 2003, 88(7), 3082-3089.
193. Linnebjerg, H.; Park, S.; Kothare, P.A.; Trautmann, M.E.; Mace, K.; Fineman, M.; Wilding, I.; Nauck, M.; Horowitz, M. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul. Pept., 2008, 151(1-3), 123-129.
194. Matikainen, N.; Manttari, S.; Schweizer, A.; Ulvestad, A.; Mills, D.; Dunning, B.E.; Foley, J.E.; Taskinen, M.R. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia, 2006, 49(9), 2049-2057.
195. Meier, J.J.; Gethmann, A.; Gotze, O.; Gallwitz, B.; Holst, J.J.; Schmidt, W.E.; Nauck, M.A. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia, 2006, 49(3), 452-458.
196. Schwartz, E.A.; Koska, J.; Mullin, M.P.; Syoufi, I.; Schwenke, D.C.; Reaven, P.D. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis, 2010, 212(1), 217-222.
197. Vella, A.; Bock, G.; Giesler, P.D.; Burton, D.B.; Serra, D.B.; Saylan, M.L.; Dunning, B.E.; Foley, J.E.; Rizza, R.A.; Camilleri, M. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes, 2007, 56(5), 1475-1480.
198. Arakawa, M.; Mita, T.; Azuma, K.; Ebato, C.; Goto, H.; Nomiyama, T.; Fujitani, Y.; Hirose, T.; Kawamori, R.; Watada, H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes, 2010, 59(4), 1030-1037.
199. Chaudhuri, A.; Ghanim, H.; Vora, M.; Sia, C.L.; Korzeniewski, K.; Dhindsa, S.; Makdissi, A.; Dandona, P. Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab., 2012, 97(1), 198-207